Researchers found a prevalence of almost 11% for postpartum PTSD in patients who underwent inductions for vaginal births.
A recent case report highlighted a link between excessive maternal-paternal HLA compatibility and recurrent pregnancy losses.
Researchers found gaps in care for minorities that may be due to systemic racism, language barriers, unequal healthcare access and more.
Adopting the updated guidelines offers significant opportunities to reduce unnecessary platelet transfusions, which are used to treat FNAIT.
Researchers have developed a novel CRISPR-based method to better understand genetic mutations in IPDs, a differential diagnosis for FNAIT.
Researchers found that maternal anti-αIIb antibodies directly target fetal hematopoietic stem cells (HSCs) in mice models of FNAIT.
A targeted immunotherapy using a specially designed fusion protein for the treatment of FNAIT has shown early promise in animal models.
Biologics like nipocalimab will soon offer a targeted approach that could transform FNAIT prevention and management.
Advancements in the preparation of platelet concentrates, often required to treat FNAIT, have the potential to improve patient care.
IVIG can prevent severe thrombocytopenia in pregnancies complicated with FNAIT, but its efficacy can vary from pregnancy to pregnancy.
